申请人:OSI Pharmaceuticals, LLC
公开号:US09096624B2
公开(公告)日:2015-08-04
Compounds of Formula 1, as shown below and defined herein:
and pharmaceutically acceptable salts, synthesis, intermediates, formulations, and methods of disease treatment therewith, including cancers mediated at least in part by FAK.
化学式为1的化合物,如下所示并在此定义:以及其药学上可接受的盐、合成、中间体、制剂和治疗疾病的方法,包括至少部分由FAK介导的癌症。